CN111699004A - 眼科疾病的治疗 - Google Patents

眼科疾病的治疗 Download PDF

Info

Publication number
CN111699004A
CN111699004A CN201980011416.4A CN201980011416A CN111699004A CN 111699004 A CN111699004 A CN 111699004A CN 201980011416 A CN201980011416 A CN 201980011416A CN 111699004 A CN111699004 A CN 111699004A
Authority
CN
China
Prior art keywords
weeks
bispecific antibody
treatment
vegf
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980011416.4A
Other languages
English (en)
Chinese (zh)
Inventor
亚伦·奥斯本
贾亚什里·萨尼
罗伯特·詹姆斯·威克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Priority to CN202510108289.7A priority Critical patent/CN119909169A/zh
Priority to CN202411925146.7A priority patent/CN119733046A/zh
Priority to CN202411926524.3A priority patent/CN119770646A/zh
Publication of CN111699004A publication Critical patent/CN111699004A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980011416.4A 2018-02-06 2019-02-05 眼科疾病的治疗 Withdrawn CN111699004A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202510108289.7A CN119909169A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411925146.7A CN119733046A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411926524.3A CN119770646A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202411925146.7A Division CN119733046A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411926524.3A Division CN119770646A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202510108289.7A Division CN119909169A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Publications (1)

Publication Number Publication Date
CN111699004A true CN111699004A (zh) 2020-09-22

Family

ID=65352014

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510108289.7A Pending CN119909169A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411925146.7A Pending CN119733046A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN201980011416.4A Withdrawn CN111699004A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411926524.3A Pending CN119770646A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202510108289.7A Pending CN119909169A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411925146.7A Pending CN119733046A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411926524.3A Pending CN119770646A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Country Status (12)

Country Link
US (2) US20210139576A1 (enExample)
EP (1) EP3749359A1 (enExample)
JP (5) JP7005772B2 (enExample)
KR (3) KR20250166355A (enExample)
CN (4) CN119909169A (enExample)
AU (3) AU2019219004B2 (enExample)
CA (1) CA3088355A1 (enExample)
IL (1) IL276383B2 (enExample)
MX (1) MX2020007527A (enExample)
SG (1) SG11202006712XA (enExample)
TW (3) TW202535932A (enExample)
WO (1) WO2019154776A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088156A1 (zh) * 2022-10-24 2024-05-02 景泽生物医药(合肥)有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
EP4010370A1 (en) * 2019-08-06 2022-06-15 F. Hoffmann-La Roche AG Personalized treatment of ophthalmologic diseases
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
CR20230114A (es) * 2020-09-04 2023-05-18 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y métodos de uso
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
EP4313148A4 (en) * 2021-03-30 2025-02-19 Abpro Corporation METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN118139628A (zh) * 2021-08-23 2024-06-04 阿维麦克思生物制药公司 用于转基因表达的组合物和方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533950A (zh) * 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
CN104428315A (zh) * 2012-07-13 2015-03-18 罗氏格黎卡特股份公司 双特异性抗-vegf/抗-ang-2抗体及其在治疗眼血管疾病中的应用
CN104582728A (zh) * 2012-08-21 2015-04-29 Opko制药公司 脂质体制剂
CN105164157A (zh) * 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
WO2016073918A1 (en) * 2014-11-07 2016-05-12 Novartis Ag Methods for treating ocular diseases
CN106999511A (zh) * 2014-12-11 2017-08-01 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
CN107001457A (zh) * 2014-11-25 2017-08-01 瑞泽恩制药公司 用于治疗血管性眼病的方法和制剂
WO2017197199A1 (en) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
CN107428826A (zh) * 2015-01-28 2017-12-01 伊莱利利公司 VEGFA/Ang2化合物
WO2017218977A2 (en) * 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533950A (zh) * 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
CN104428315A (zh) * 2012-07-13 2015-03-18 罗氏格黎卡特股份公司 双特异性抗-vegf/抗-ang-2抗体及其在治疗眼血管疾病中的应用
CN104582728A (zh) * 2012-08-21 2015-04-29 Opko制药公司 脂质体制剂
CN105164157A (zh) * 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
WO2016073918A1 (en) * 2014-11-07 2016-05-12 Novartis Ag Methods for treating ocular diseases
CN106999581A (zh) * 2014-11-07 2017-08-01 诺华股份有限公司 含有高浓度抗vegf抗体的稳定蛋白质溶液剂型
CN107001457A (zh) * 2014-11-25 2017-08-01 瑞泽恩制药公司 用于治疗血管性眼病的方法和制剂
CN106999511A (zh) * 2014-12-11 2017-08-01 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
CN107428826A (zh) * 2015-01-28 2017-12-01 伊莱利利公司 VEGFA/Ang2化合物
WO2017197199A1 (en) * 2016-05-13 2017-11-16 Askgene Pharma Inc. Novel angiopoietin 2, vegf dual antagonists
WO2017218977A2 (en) * 2016-06-17 2017-12-21 Genentech, Inc. Purification of multispecific antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAKRAVARTHY U等: "Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration", 《OPHTHALMOL RETINA》, vol. 1, no. 6, 23 May 2017 (2017-05-23), pages 474 - 485, XP002790566, DOI: 10.1016/j.oret.2017.03.003 *
HOFFMANN-LA ROCH: "NCT02484690，ClinicalTrials.gov", pages 1 - 7, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/history/NCT02484690?V_15=View#StudyPageTop> *
HOFFMANN-LA ROCH: "NCT02699450, ClinicalTrials.gov", pages 1 - 8, Retrieved from the Internet <URL:https://classic.clinicaltrials.gov/ct2/history/NCT02699450?V_9=View#StudyPageTop> *
REGULA JT等: "Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases", 《EMBO MOL MED》, vol. 8, no. 11, pages 1265 - 1288, XP055573583, DOI: 10.15252/emmm.201505889 *
WORLD HEALTH ORGANIZATION: "International nonproprietary names for pharmaceutical substances (‎INN)‎: proposed INN: list 118", 《WHO DRUG INFORMATION》, vol. 31, no. 4, 31 December 2017 (2017-12-31), pages 635 - 754 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024088156A1 (zh) * 2022-10-24 2024-05-02 景泽生物医药(合肥)有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Also Published As

Publication number Publication date
KR20250166355A (ko) 2025-11-27
JP7273204B2 (ja) 2023-05-12
CA3088355A1 (en) 2019-08-15
MX2020007527A (es) 2020-09-09
TWI885720B (zh) 2025-06-01
JP7646727B2 (ja) 2025-03-17
AU2019219004A1 (en) 2020-07-16
SG11202006712XA (en) 2020-08-28
AU2025220842A1 (en) 2025-09-11
KR20200119274A (ko) 2020-10-19
TW202419464A (zh) 2024-05-16
JP2021506947A (ja) 2021-02-22
TW202535932A (zh) 2025-09-16
EP3749359A1 (en) 2020-12-16
IL276383B2 (en) 2024-01-01
JP2023099094A (ja) 2023-07-11
AU2019219004B2 (en) 2025-06-05
TWI831764B (zh) 2024-02-11
US20210139576A1 (en) 2021-05-13
IL276383B1 (en) 2023-09-01
AU2025220841A1 (en) 2025-09-11
JP2022046738A (ja) 2022-03-23
JP2025084977A (ja) 2025-06-03
US20230416353A1 (en) 2023-12-28
TW202000700A (zh) 2020-01-01
WO2019154776A1 (en) 2019-08-15
KR20240093772A (ko) 2024-06-24
CN119909169A (zh) 2025-05-02
JP7005772B2 (ja) 2022-02-10
JP2025084976A (ja) 2025-06-03
CN119770646A (zh) 2025-04-08
CN119733046A (zh) 2025-04-01
IL276383A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JP7646727B2 (ja) 眼科疾患の処置
TWI881273B (zh) 眼科疾病之個人化治療
HK40034720A (zh) 眼科疾病的治疗
HK40065038A (en) Personalized treatment of ophthalmologic diseases
HK40065038B (zh) 眼科疾病的个性化治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034720

Country of ref document: HK

WW01 Invention patent application withdrawn after publication

Application publication date: 20200922

WW01 Invention patent application withdrawn after publication